HYTERA
21.4.2022 14:20:12 CEST | Business Wire | Press release
Hytera (SZSE: 002583), the leading global provider of professional communications technologies and solutions, has released its annual Corporate Responsibility Report recently, summarizing the company’s environmental, social and governance (ESG) performance in 2021.
As a leading player in the Professional Mobile Radio (PMR) industry, Hytera has a long history of providing stakeholders with transparent information on its annual sales and ESG performance. The report features successes achieved last year, including its performance on business development as well as environmental sustainability, as well as technical support for public events and disaster relief around the world.
Continuous Innovation to Lead the Industry Transformation
Hytera is focused on technological innovation to drive business development. By the end of 2021, Hytera's total R&D investment had increased to USD 162 million, accounting for 18.05% of the sales revenue, and R&D personnel accounted for over 40% of the staff. Hytera has filed for 2,892 patents in total, including 507 PCT patents, 291 overseas patents, and 79 5G and LEO satellites patents; the overall patent licensing rate has reached 93.32%.
Hytera’s PMR-LTE convergent solutions have been recognized by the market in the past few years and so far, Hytera has deployed more than 200 converged multi-media PTT platforms globally and has been cooperating with over 20 local operators to better serve more vertical industry uses. In 2021, the International Critical Communications Awards (ICAA) awarded Hytera the “Best Use of Critical Communications in Utilities” in recognition of its Hytalk PoC customer case using PMR-LTE convergent solutions.
Better Operation for Environmental Sustainability
Hytera is dedicated to operating with sustainable business practices, including energy saving, emission reduction, and green and recyclable product manufacturing management. In 2021, Hytera’s electricity consumption decreased by 25% YOY, and general industrial waste dropped by 22% YOY.
In 2021, Hytera's subsidiaries HMF and Teltronic have organized multiple Green Travel campaigns, which reduced 809 kg of carbon dioxide emissions, exhaust gas and noise pollution by bike cycling instead of car driving in commutes to work.
Participation in Social Activities and Community Service to Repay the Society
Hytera has actively contributed its capabilities to improve disease prevention, for example, donating two-way radios to staff in hospitals, medical teams and security departments around the world in order to combat COVID-19.
Hytera also actively participated in various social welfare activities. In late 2021, Hytera supported Tinzert Elementary School of Morocco with a donation of warm coats and medical masks, and renovated the school to withstand the coldness of the mountainous area. Besides, Hytera was recognized as the science and technology education center and set up technology tutorials for both students and adults utilizing the PMR technologies and devices.
In terms of disaster relief, Hytera provided professional communication supports to the local rescue teams for flood relief in Henan China, and western Germany. Hytera also provided support to Blue Sky Rescue (BSR) volunteers in Europe to empower their post-disaster rescue work.
This year, the world faced greater global challenges than ever before, necessitating the use of professional technologies and products. Hytera’s innovations in communications technologies are revolutionizing industries and addressing some of the society's serious challenges.
Hytera is proud of its efforts to protect the environment and keep the community safe, and everything it does is guided by the code of ethics and business conduct.
Hytera will continue to make contributions to the people, communities, and the environment in order to make the world more intelligently connected and to help shape a better future for everybody.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005570/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom